NP outlines the issues in a CC and there were init

NP outlines the issues in a CC and there were initially 3 (if I’m remembering correctly), he then added the receptor occupancy data as another issue a month or so later. The issues were a small discrepancy with syringe packaging, 700mg data, and I don’t recall the third.